Ultragenyx Pharmaceutical Inc. Stock
A very strong showing by Ultragenyx Pharmaceutical Inc. today, with an increase of €1.06 (4.720%) compared to yesterday's price.
The stock is an absolute favorite of our community with 25 Buy predictions and no Sell predictions.
Based on the current price of 23.54 € the target price of 50 € shows a potential of 112.4% for Ultragenyx Pharmaceutical Inc. which would more than double the current price.
Pros and Cons of Ultragenyx Pharmaceutical Inc. in the next few years
Pros
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
B****
Cons
?
G***** c******* t* c**********
?
S********** s********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Ultragenyx Pharmaceutical Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. | 4.720% | 9.387% | -21.794% | -0.254% | 40.119% | -28.232% | -68.403% |
| Ligand Pharmaceuticals | -3.820% | -0.781% | -9.286% | 117.094% | 53.012% | 313.008% | 171.194% |
| United Therapeutics | -0.580% | 3.809% | -3.937% | 79.784% | 9.057% | 115.741% | 156.044% |
| Ionis Pharmaceuticals Inc. | 1.990% | 8.773% | -33.915% | 39.931% | -28.119% | 35.356% | 47.985% |
Comments
Ultragenyx Pharmaceutical (RARE) had its price target lowered by Wells Fargo & Company from $47.00 to $45.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for RARE provided by MarketBeat
Ultragenyx Pharmaceutical (RARE) had its price target lowered by Guggenheim from $43.00 to $35.00. They now have a "buy" rating on the stock.
Show more
Ratings data for RARE provided by MarketBeat
Ultragenyx Pharmaceutical (RARE) had its price target raised by Royal Bank Of Canada from $35.00 to $40.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for RARE provided by MarketBeat
News
Ultragenyx Pharmaceutical Q2 Earnings Call Highlights
Key Points
- Interested in Ultragenyx Pharmaceutical Inc.? Here are five stocks we like better.
- Ultragenyx reported record Q2 revenue of $214 million, led by Crysvita’s $156 million contribution
What to Know About This Fund's $5.4 Million Ultragenyx Purchase as Shares Slip 30% in One Year
On May 14, 2026, Krensavage Asset Management disclosed it bought 241,245 shares of Ultragenyx Pharmaceutical (NASDAQ:RARE), an estimated $5.43 million trade based on quarterly average pricing.
